Cargando…

Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury

Permeation of the small intestinal mucosa is a key mechanism in the induction of enteropathy. We investigated the effect of rebamipide in healthy subjects with diclofenac-induced small intestinal damage and permeability. In this crossover study, each treatment period was 1 week with a 4-week washout...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Yoshitsugi, Sasaki, Makoto, Funaki, Yasushi, Ogasawara, Naotaka, Mizuno, Mari, Iida, Akihito, Izawa, Shinya, Masui, Ryuta, Kondo, Yoshihiro, Tamura, Yasuhiro, Yanamoto, Kenichiro, Noda, Hisatsugu, Tanabe, Atsushi, Okaniwa, Noriko, Yamaguchi, Yoshiharu, Kasugai, Kunio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705150/
https://www.ncbi.nlm.nih.gov/pubmed/23874071
http://dx.doi.org/10.3164/jcbn.12-116
_version_ 1782476392838987776
author Ito, Yoshitsugi
Sasaki, Makoto
Funaki, Yasushi
Ogasawara, Naotaka
Mizuno, Mari
Iida, Akihito
Izawa, Shinya
Masui, Ryuta
Kondo, Yoshihiro
Tamura, Yasuhiro
Yanamoto, Kenichiro
Noda, Hisatsugu
Tanabe, Atsushi
Okaniwa, Noriko
Yamaguchi, Yoshiharu
Kasugai, Kunio
author_facet Ito, Yoshitsugi
Sasaki, Makoto
Funaki, Yasushi
Ogasawara, Naotaka
Mizuno, Mari
Iida, Akihito
Izawa, Shinya
Masui, Ryuta
Kondo, Yoshihiro
Tamura, Yasuhiro
Yanamoto, Kenichiro
Noda, Hisatsugu
Tanabe, Atsushi
Okaniwa, Noriko
Yamaguchi, Yoshiharu
Kasugai, Kunio
author_sort Ito, Yoshitsugi
collection PubMed
description Permeation of the small intestinal mucosa is a key mechanism in the induction of enteropathy. We investigated the effect of rebamipide in healthy subjects with diclofenac-induced small intestinal damage and permeability. In this crossover study, each treatment period was 1 week with a 4-week washout period. Diclofenac (75 mg/day) and omeprazole (20 mg/day) plus rebamipide (300 mg/day) or placebo were administered. Capsule endoscopy and a sugar permeability test were performed on days 1 and 7 in each period. Ten healthy subjects were enrolled. Small intestinal injuries were observed on day 7 in 6 of 10 subjects in both groups. Urinary excretion of administered lactulose increased from 0.30% to 0.50% of the initial dose during the first treatment period in the placebo group, and from 0.13% to 0.33% in the rebamipide group. Despite recovery from small-intestinal mucosal damage, the increased permeability in both groups resulted in sustained high levels of lactulose (0.50% to 1.06% in the placebo group and 0.33% to 1.12% in the rebamipide group) through the 4-week washout period. Diclofenac administration induced enteropathy and hyperpermeability of the small intestine. The sustained hyperpermeability during the washout period may indicate the presence of invisible fragility.
format Online
Article
Text
id pubmed-3705150
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher the Society for Free Radical Research Japan
record_format MEDLINE/PubMed
spelling pubmed-37051502013-07-19 Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury Ito, Yoshitsugi Sasaki, Makoto Funaki, Yasushi Ogasawara, Naotaka Mizuno, Mari Iida, Akihito Izawa, Shinya Masui, Ryuta Kondo, Yoshihiro Tamura, Yasuhiro Yanamoto, Kenichiro Noda, Hisatsugu Tanabe, Atsushi Okaniwa, Noriko Yamaguchi, Yoshiharu Kasugai, Kunio J Clin Biochem Nutr Original Article Permeation of the small intestinal mucosa is a key mechanism in the induction of enteropathy. We investigated the effect of rebamipide in healthy subjects with diclofenac-induced small intestinal damage and permeability. In this crossover study, each treatment period was 1 week with a 4-week washout period. Diclofenac (75 mg/day) and omeprazole (20 mg/day) plus rebamipide (300 mg/day) or placebo were administered. Capsule endoscopy and a sugar permeability test were performed on days 1 and 7 in each period. Ten healthy subjects were enrolled. Small intestinal injuries were observed on day 7 in 6 of 10 subjects in both groups. Urinary excretion of administered lactulose increased from 0.30% to 0.50% of the initial dose during the first treatment period in the placebo group, and from 0.13% to 0.33% in the rebamipide group. Despite recovery from small-intestinal mucosal damage, the increased permeability in both groups resulted in sustained high levels of lactulose (0.50% to 1.06% in the placebo group and 0.33% to 1.12% in the rebamipide group) through the 4-week washout period. Diclofenac administration induced enteropathy and hyperpermeability of the small intestine. The sustained hyperpermeability during the washout period may indicate the presence of invisible fragility. the Society for Free Radical Research Japan 2013-07 2013-04-09 /pmc/articles/PMC3705150/ /pubmed/23874071 http://dx.doi.org/10.3164/jcbn.12-116 Text en Copyright © 2013 JCBN This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ito, Yoshitsugi
Sasaki, Makoto
Funaki, Yasushi
Ogasawara, Naotaka
Mizuno, Mari
Iida, Akihito
Izawa, Shinya
Masui, Ryuta
Kondo, Yoshihiro
Tamura, Yasuhiro
Yanamoto, Kenichiro
Noda, Hisatsugu
Tanabe, Atsushi
Okaniwa, Noriko
Yamaguchi, Yoshiharu
Kasugai, Kunio
Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury
title Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury
title_full Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury
title_fullStr Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury
title_full_unstemmed Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury
title_short Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury
title_sort nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705150/
https://www.ncbi.nlm.nih.gov/pubmed/23874071
http://dx.doi.org/10.3164/jcbn.12-116
work_keys_str_mv AT itoyoshitsugi nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT sasakimakoto nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT funakiyasushi nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT ogasawaranaotaka nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT mizunomari nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT iidaakihito nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT izawashinya nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT masuiryuta nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT kondoyoshihiro nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT tamurayasuhiro nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT yanamotokenichiro nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT nodahisatsugu nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT tanabeatsushi nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT okaniwanoriko nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT yamaguchiyoshiharu nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury
AT kasugaikunio nonsteroidalantiinflammatorydruginducedvisibleandinvisiblesmallintestinalinjury